Compare Stocks

Date Range: 

 Becton, Dickinson andBoston ScientificStrykerBaxter InternationalDexCom
SymbolNYSE:BDXNYSE:BSXNYSE:SYKNYSE:BAXNASDAQ:DXCM
Price Information
Current Price$242.87$42.89$251.93$84.13$350.16
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score2.22.02.01.92.1
Analysis Score2.32.42.31.34.4
Community Score2.32.72.62.73.0
Dividend Score3.30.01.72.50.0
Ownership Score1.71.71.71.71.7
Earnings & Valuation Score1.33.11.91.31.3
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$280.22$46.28$265.00$91.18$456.60
% Upside from Price Target15.38% upside7.90% upside5.19% upside8.38% upside30.40% upside
Trade Information
Market Cap$71.66 billion$61.44 billion$96.44 billion$43.49 billion$33.14 billion
Beta0.790.870.870.650.86
Average Volume1,345,9849,316,8151,194,6082,647,635830,444
Sales & Book Value
Annual Revenue$17.12 billion$10.74 billion$14.88 billion$11.36 billion$1.48 billion
Price / Sales4.125.686.383.7222.94
Cashflow$16.39 per share$2.84 per share$10.85 per share$5.22 per share$2.31 per share
Price / Cash14.8215.1223.2316.11151.66
Book Value$81.98 per share$9.96 per share$34.23 per share$15.50 per share$9.64 per share
Price / Book2.964.317.365.4336.32
Profitability
Net Income$874 million$4.70 billion$2.08 billion$1.00 billion$101.10 million
EPS$10.20$1.58$8.26$3.31$1.84
Trailing P/E Ratio88.9616.4354.6547.80144.69
Forward P/E Ratio18.1426.6427.7224.46105.79
P/E Growth2.342.302.792.536.15
Net Margins5.11%36.59%12.35%7.90%12.69%
Return on Equity (ROE)13.30%11.77%20.94%20.81%27.29%
Return on Assets (ROA)5.60%5.57%8.77%8.78%10.45%
Dividend
Annual Payout$3.32N/A$2.52$0.98N/A
Dividend Yield1.37%N/A1.00%1.16%N/A
Three-Year Dividend Growth8.84%N/A34.96%56.56%N/A
Payout Ratio32.55%N/A30.51%29.61%N/A
Years of Consecutive Dividend Growth50 YearsN/A1 Years5 YearsN/A
Debt
Debt-to-Equity Ratio0.72%0.60%0.92%0.67%1.10%
Current Ratio1.54%1.87%2.89%2.64%6.39%
Quick Ratio1.07%1.42%2.15%2.06%6.00%
Ownership Information
Institutional Ownership Percentage83.22%90.70%71.46%82.89%94.06%
Insider Ownership Percentage0.76%0.70%6.80%0.13%0.69%
Miscellaneous
Employees70,00036,00043,00050,0005,500
Shares Outstanding290.56 million1.42 billion376.75 million502.85 million96.71 million
Next Earnings Date8/5/2021 (Estimated)8/4/2021 (Estimated)7/29/2021 (Estimated)7/29/2021 (Estimated)7/27/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Buy Or Fear DexCom Stock: DXCMs 15% Decline In A Year Despite Revenues Increasing 31% YoY Over The Last 4 Quarters Looks Like A Buying Opportunity. The stock has gained 497% since the end of 2017 due to favorable changes in the companys P/E Multiple over this period - TrefisBuy Or Fear DexCom Stock: DXCM's 15% Decline In A Year Despite Revenues Increasing 31% YoY Over The Last 4 Quarters Looks Like A Buying Opportunity. The stock has gained 497% since the end of 2017 due to favorable changes in the company's P/E Multiple over this period - Trefis
trefis.com - May 11 at 10:50 AM
Does DexCom Inc. (NASDAQ:DXCM) Still Need To Convince Analysts?Does DexCom Inc. (NASDAQ:DXCM) Still Need To Convince Analysts?
stocksregister.com - May 10 at 9:26 AM
10 Beaten-Down Stocks That Could See a Rebound10 Beaten-Down Stocks That Could See a Rebound
finance.yahoo.com - May 10 at 9:26 AM
DexCom, Inc.s (NASDAQ:DXCM) Business Is Trailing The Market But Its Shares Arent - NasdaqDexCom, Inc.'s (NASDAQ:DXCM) Business Is Trailing The Market But Its Shares Aren't - Nasdaq
nasdaq.com - May 7 at 8:05 AM
Focused on diabetes, Eli Lilly inks integration deals with Roche, Dexcom, Glooko and more - Mobihealth NewsFocused on diabetes, Eli Lilly inks integration deals with Roche, Dexcom, Glooko and more - Mobihealth News
mobihealthnews.com - May 6 at 4:58 PM
Canaccord Genuity Increases DexCom (NASDAQ:DXCM) Price Target to $455.00Canaccord Genuity Increases DexCom (NASDAQ:DXCM) Price Target to $455.00
americanbankingnews.com - May 6 at 2:02 PM
DexCom (NASDAQ:DXCM) Releases FY 2021 Earnings GuidanceDexCom (NASDAQ:DXCM) Releases FY 2021 Earnings Guidance
americanbankingnews.com - May 6 at 12:43 PM
DexCom (NASDAQ:DXCM) PT Raised to $466.00 at Raymond JamesDexCom (NASDAQ:DXCM) PT Raised to $466.00 at Raymond James
americanbankingnews.com - May 6 at 11:58 AM
Dexcom Inc (DXCM) Chairman, CEO & President Kevin R Sayer Sold $2.1 million of Shares - Yahoo FinanceDexcom Inc (DXCM) Chairman, CEO & President Kevin R Sayer Sold $2.1 million of Shares - Yahoo Finance
finance.yahoo.com - May 6 at 11:58 AM
Lilly inks smart insulin pen deals with Roche, Dexcom and more - FierceBiotechLilly inks smart insulin pen deals with Roche, Dexcom and more - FierceBiotech
fiercebiotech.com - May 6 at 11:58 AM
Can Dexcom Stock Rebound After The Recent 11% Drop? - TrefisCan Dexcom Stock Rebound After The Recent 11% Drop? - Trefis
trefis.com - May 6 at 11:58 AM
DexCom (NASDAQ:DXCM) Price Target Raised to $488.00DexCom (NASDAQ:DXCM) Price Target Raised to $488.00
americanbankingnews.com - May 6 at 10:13 AM
DexCom (NASDAQ:DXCM) Price Target Raised to $466.00DexCom (NASDAQ:DXCM) Price Target Raised to $466.00
marketbeat.com - May 6 at 8:51 AM
Dexcom Inc (DXCM) Chairman, CE - GuruFocus.comDexcom Inc (DXCM) Chairman, CE - GuruFocus.com
gurufocus.com - May 5 at 11:43 PM
DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer Sells 5,535 SharesDexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer Sells 5,535 Shares
americanbankingnews.com - May 5 at 7:58 PM
How I Battle Mental Health Woes with Type 1 Diabetes - HealthlineHow I Battle Mental Health Woes with Type 1 Diabetes - Healthline
healthline.com - May 5 at 6:43 PM
Was The Smart Money Right About DexCom (DXCM)? - Yahoo FinanceWas The Smart Money Right About DexCom (DXCM)? - Yahoo Finance
finance.yahoo.com - May 4 at 7:44 PM
Was The Smart Money Right About DexCom (DXCM)?Was The Smart Money Right About DexCom (DXCM)?
feedproxy.google.com - May 4 at 7:05 PM
Analysts Conflicted on These Healthcare Names: Addus Homecare (ADUS), Dexcom (DXCM) and Qiagen (QGEN) - Smarter AnalystAnalysts Conflicted on These Healthcare Names: Addus Homecare (ADUS), Dexcom (DXCM) and Qiagen (QGEN) - Smarter Analyst
smarteranalyst.com - May 4 at 2:43 PM
Leerink Partners Stick to Their Buy Rating for Dexcom By Investing.com - Investing.comLeerink Partners Stick to Their Buy Rating for Dexcom By Investing.com - Investing.com
investing.com - May 3 at 4:00 AM
SVB Leerink Brokers Reduce Earnings Estimates for DexCom, Inc. (NASDAQ:DXCM)SVB Leerink Brokers Reduce Earnings Estimates for DexCom, Inc. (NASDAQ:DXCM)
americanbankingnews.com - May 3 at 2:30 AM
Dexcoms shares sink despite better-than-expected first quarter financial results - The San Diego Union-TribuneDexcom's shares sink despite better-than-expected first quarter financial results - The San Diego Union-Tribune
sandiegouniontribune.com - May 1 at 4:03 PM
DexCom Inc. stock falls Friday, underperforms market - MarketWatchDexCom Inc. stock falls Friday, underperforms market - MarketWatch
marketwatch.com - April 30 at 7:59 PM
DexCom: Q1 Earnings Snapshot - Albany Times UnionDexCom: Q1 Earnings Snapshot - Albany Times Union
timesunion.com - April 30 at 7:59 PM
Dexcom stock takes a tumble, despite reporting increased Q1 revenue - Mobihealth NewsDexcom stock takes a tumble, despite reporting increased Q1 revenue - Mobihealth News
mobihealthnews.com - April 30 at 7:59 PM
DexCom Drops After Revenue Guidance Misses - TheStreetDexCom Drops After Revenue Guidance Misses - TheStreet
thestreet.com - April 30 at 2:59 PM
Citigroup Increases DexCom (NASDAQ:DXCM) Price Target to $488.00Citigroup Increases DexCom (NASDAQ:DXCM) Price Target to $488.00
marketbeat.com - April 30 at 1:00 PM
DateCompanyBrokerageAction
5/7/2021Becton, Dickinson andSVB LeerinkLower Price Target
2/5/2021Becton, Dickinson andCitigroupBoost Price Target
2/4/2021Becton, Dickinson andPiper SandlerBoost Price Target
1/29/2021Becton, Dickinson andRaymond JamesBoost Price Target
12/15/2020Becton, Dickinson andThe Goldman Sachs GroupDowngrade
12/15/2020Becton, Dickinson andWells Fargo & CompanyDowngrade
12/15/2020Becton, Dickinson andMorgan StanleyUpgrade
8/10/2020Becton, Dickinson andUBS GroupBoost Price Target
7/9/2020Becton, Dickinson andBarclaysUpgrade
7/2/2020Becton, Dickinson andWilliam BlairReiterated Rating
5/12/2020Becton, Dickinson andKeyCorpReiterated Rating
5/8/2020Becton, Dickinson andCfraLower Price Target
4/29/2021Boston ScientificTruistBoost Price Target
4/29/2021Boston ScientificCanaccord GenuityBoost Price Target
4/29/2021Boston ScientificDeutsche Bank AktiengesellschaftBoost Price Target
4/21/2021Boston ScientificAtlantic SecuritiesInitiated Coverage
2/12/2021Boston ScientificNeedham & Company LLCBoost Price Target
12/8/2020Boston ScientificBTIG ResearchReiterated Rating
11/18/2020Boston ScientificCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target
11/18/2020Boston ScientificSmith Barney CitigroupLower Price Target
9/11/2020Boston ScientificWolfe ResearchInitiated Coverage
7/30/2020Boston ScientificStifel NicolausBoost Price Target
4/28/2021StrykerTruist SecuritiesBoost Price Target
4/28/2021StrykerOppenheimerBoost Price Target
4/28/2021StrykerCowenBoost Price Target
4/28/2021StrykerRobert W. BairdBoost Price Target
3/2/2021StrykerJPMorgan Chase & Co.Boost Price Target
1/28/2021StrykerCredit Suisse GroupLower Price Target
9/4/2020Baxter InternationalArgusDowngrade
(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.